Aston SCI

A New Vaccine Approach for Ovarian Cancer Patients SEOUL, South Korea, Sept. 12, 2023 /PRNewswire/ -- Aston Sci. is proud to announce that it has received Phase 2 Clinical Investigational New Drug (IND) approval from the U.S. Food and Drug Administration (FDA) for its innovative cancer vaccine, AST-201, designed specifically for ovarian cancer. This milestone achievement, known as the CornerStone-004 program, marks a significant step forward in Aston Sci.'s fight against women's cancers. Study Highlights and the Primary Objective: The study is a randomized controlled trial designed to assess the clinical efficacy and safety of the plasmid-based DNA vaccine AST-201 when administered alongside standard adjuvant chemotherapy (Paclitaxel/Carboplatin), for patients with newly diagnosed Stage III advanced ovarian cancer following surgical intervention. The primary objective of this study is to evaluate the clinical efficacy of AST-201 compared to a placebo, as measured by the progression-free survival (PFS) rate. Aston Sci.'s Pipeline Expansion: With this milestone, Aston Sci.'s pipeline has expanded to include two drug candidates in multinational Phase 2 clinical trials: AST-201 for ovarian cancer and AST-301 for breast and gastric cancer. This milestone underscores Aston Sci.'s position as a frontrunner in the field, with a total of four drugs in advanced clinical stages. Aston Sci. is currently conducting or planning four CornerStone clinical programs in the United States, Taiwan, Korea and Europe. A New Vaccine Approach for Ovarian Cancer Patients: "In a global environment where approved immunotherapies for ovarian cancer remain scarce, our dedicated efforts are focused on delivering a safer and more advanced treatment option for ovarian cancer patients. We are committed to sharing our results at the earliest opportunity," said Dr. Hun Jung, Head of R&D Division at Aston Sci. Inc. "We will expand clinical research across various indications and reaffirm our expertise in the field of cancer vaccine development." About Aston Sci. Inc. Aston Sci. Inc. is a clinical-stage biopharmaceutical company led by a team of global pharmaceutical experts. Specializing in innovative immunotherapies, including therapeutic cancer vaccines, Aston Sci. focuses on enhancing T-cell immune responses against specific antigens, triggering cancer cell apoptosis. Central to our mission is the Th-Vac® platform. This platform, grounded in immune informatics, facilitates continuous epitope discovery, serving as the cornerstone of our ongoing efforts in therapeutic vaccine development. Headquartered in Seoul, South Korea, with a U.S. office in Seattle, Washington, Aston Sci. is deeply committed to delivering advanced treatments and preventing cancer recurrence, ultimately striving for safer and more effective options for cancer patients worldwide. Media Contact: Kevin KP Jang Public Affairs Manager [email protected] SOURCE Aston Sci. Inc.

Ely Reeves Callaway (1947-2023). Photo Credit, all images: Callaway Cars American automotive company Callaway Cars (Old Lyme, Conn., U.S.) announces with deepest sadness the passing of its founder and CEO, Ely Reeves Callaway III, on July 11, 2023, at his home in Newport Beach, Calif., U.S. from injuries sustained after a fall. Reeves was a notable figure in the world of high-performance automobiles. Entirely self-taught, Reeves founded the company in 1977 from his garage in Old Lyme, Conn., U.S. His first product success was an aftermarket turbo kit for BMW, which automotive journalist Don Sherman reviewed favorably that year in Car and Driver. The rest was history as Reeves, a Formula Vee champion driver prior to becoming a constructor, moved with his customary speed to open Callaway Cars’ first headquarters. Over the four decades since, Reeves and Callaway Cars have continued to earn top accolades from media, the automotive industry and the global motorsports world. His performance and design innovations have delivered track and road-going successes for global marques, including BMW, Alfa Romeo, Aston Martin, Land Rover, Mazda and General Motors (GM), who looked to Callaway’s innovation, creativity, agility and performance to help accomplish their goals. Reeves is perhaps best known for his work with Corvette, a deep and high-level relationship with the American sports car manufacturer that began in 1987 and culminated with two industry firsts: The Callaway Twin Turbo Corvette “B2K” designation, and a Twin Turbo Corvette, dubbed “The Sledgehammer,” which, in 1989, set a production car top speed record of 254.76 miles per hour. In 1994, Reeves launched a Germany-based racing unit, Callaway Competition, with partners Ernst Wöhr and Giovanni Ciccone. International recognition was achieved by their successes at the 24 Hours of Le Mans, and later a European GT racing team which ultimately led to authorization by GM to construct and homologate C6- and C7-generation GT3 race cars for international competition. Reeves is said to be one of the last and most successful one-man, single-vision practitioners of hyper-performing internal combustion automobiles. It’s a rare-air field that includes the likes of Ettore Bugatti, Ferry Porsche and Enzo Ferrari, to name a few. His vision, creativity and innovation encompassed not only automotive engineering, but aviation and aerospace as well with Callaway Carbon Inc. (Temecula, Calif., U.S.) which performs custom car upgrades with carbon fiber conversion kits. A longtime helicopter pilot and board director for Kaman Corp. (Bloomfield, Conn., U.S.), Reeves was, in recent years, a founding adviser to a hydrogen-powered and composite-intensive, blended-wing aircraft startup with funding from NASA and the Air Force. “Thanks to Reeves’ visionary entrepreneurial spirit, Callaway Cars will continue to innovate and grow in the 21st century, inspired by his unique, extraordinary vision, and by his personal example of integrity, resourcefulness and leadership as our founder,” says his son, Peter Reeves Callaway, the company’s president. “Dad’s passion for making beautifully designed and crafted machines can be seen in each and every project, and we remain devoted to executing to the highest standards, in true Callaway fashion. He was rarely found doing anything other than working towards the next milestone for the company. He was a charismatic leader with a sense of humor that we will all remember through various ‘Reeves-isms.’ I feel fortunate to have grown up working with him and the company.” The first son of Ely Reeves Callaway, Jr., the founder of Callaway Golf, and brother of publisher Nicholas Callaway, Reeves proudly epitomized the entrepreneurial Callaway family tradition of making the finest goods that enhance an individual’s enjoyment, performance and lifestyle. A true gentleman, he was the devoted father of four and grandfather of two. His large circle of friends, colleagues and admirers around the world will mourn his passing and miss him deeply.

ENSTONE, England, July 5 (Reuters) - The seven British-based Formula One teams have asked the government to help ease post-Brexit border crossing and permit problems and are hopeful of a solution, Alpine principal Otmar Szafnauer said on Wednesday. Team bosses, along with Formula One head Stefano Domenicali and other representatives, attended a meeting at Downing Street with Culture Secretary Lucy Frazer on Tuesday ahead of this weekend's British Grand Prix. "We had a good meeting with the government and just asked them for their support for motorsport in general, promoting the fact that we're working hard at becoming more sustainable," Szafnauer told Reuters. "Also we asked them for help with crossing the border. "It's doable, but its not efficient," he said of the current situation. "It's difficult. Also the movement of people with work permits. If they could just help in that area that would be great. "They do something similar with the entertainment industry so they said 'well if we got it done there we should look at Formula One in the same way and try to get it done'. So they were positive." Britain's departure from the European Union ended freedom of movement for EU citizens in Britain, as well as for goods and services. The motorsport industry employs more than 40,000 people in Britain with an annual turnover of 9 billion pounds ($11.43 billion), according to the Motorsport Industry Association. Renault-owned Alpine have their Formula One factory at Enstone in central England, a short drive from the British Grand Prix track at Silverstone, with more than 900 employees from many countries. The engines are made in France by Renault at Viry-Chatillon near Paris. Alpine's sportscar factory is also in France, at Dieppe. Other British-based teams are Mercedes, McLaren, Williams, Red Bull, Haas and Aston Martin. Ferrari and Red Bull-owned AlphaTauri are based in Italy and Alfa Romeo/Sauber in Switzerland. "Car parts, every time you (go) back and forth, it is problematic. It's not efficient," said Szafnauer. "It could be a lot better. It used to be a lot better before Brexit." ($1 = 0.7876 pounds) Reporting by Alan Baldwin, editing by Toby Davis Our Standards: The Thomson Reuters Trust Principles.